Last Updated: OCTOBER 2023

Men with low total testosterone, often defined by a threshold below 300 ng/dL, face a significantly increased risk of adverse health outcomes. Recent landmark research, such as the TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), involving over 5,000 men, found no increased risk of major adverse cardiovascular events (MACE) in middle-aged and older men with hypogonadism treated with testosterone replacement therapy (TRT). This finding directly challenges older assumptions and aligns with the FDA’s ongoing reassessment of cardiovascular risk warnings for testosterone products. Understanding how TRT impacts lipid profiles—cholesterol, HDL, LDL, and triglycerides—is crucial for informed health management and maximizing the benefits of therapy.

Understanding Your Lipid Panel on TRT

A lipid panel is a standard blood test that measures the fats and fatty substances in your blood. These include total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Each plays a distinct role in cardiovascular health, and TRT can influence them in specific ways.

Optimal lipid ranges are generally:

Total Cholesterol: Below 200 mg/dL
HDL Cholesterol: 40 mg/dL or higher (preferably 60 mg/dL or higher for cardio protection)
LDL Cholesterol: Below 100 mg/dL (or below 70 mg/dL for individuals with existing heart disease)
Triglycerides: Below 150 mg/dL

The impact of TRT on these markers is complex and often dependent on baseline levels, individual metabolic factors, and the specific TRT protocol.

High-Density Lipoprotein (HDL) Cholesterol

HDL is often referred to as “good” cholesterol because it helps remove excess cholesterol from the arteries, transporting it back to the liver for excretion. On TRT, a modest decrease in HDL levels is a commonly observed effect.

For instance, a controlled study by Bagatell et al. in 1994, published in the Journal of Clinical Endocrinology & Metabolism, administered 200mg/week of testosterone enanthate for 20 weeks to healthy young men. The study reported a 13% fall in HDL-C during treatment, which returned to baseline levels within one month of cessation. This decrease is generally mild with physiological TRT doses and rarely drops below clinically concerning thresholds (typically <30 mg/dL) for most men, unless supraphysiological doses are used.

The mechanism behind this reduction is thought to involve increased hepatic lipase activity, an enzyme that metabolizes HDL particles. While a decrease in HDL is generally considered undesirable, the overall cardiovascular risk profile must be considered in context, especially given the positive effects of TRT on other markers and overall metabolic health.

Low-Density Lipoprotein (LDL) Cholesterol

LDL is often called “bad” cholesterol because high levels can lead to plaque buildup in arteries. The impact of TRT on LDL cholesterol is less consistent than for HDL. Many studies show either no significant change or a modest decrease in LDL levels, particularly in men who are obese or have metabolic syndrome.

Some research indicates that TRT can improve insulin sensitivity and body composition, leading to a favorable impact on LDL in these populations. For example, a meta-analysis published in the Journal of the American Heart Association in 2017 found that testosterone therapy significantly decreased total cholesterol and LDL cholesterol in hypogonadal men with metabolic syndrome. In healthy, non-obese hypogonadal men, the change in LDL might be negligible or slight.

Total Cholesterol and Triglycerides

Total cholesterol is the sum of HDL, LDL, and 20% of your triglyceride levels. Due to the variable effects on HDL and LDL, total cholesterol levels on TRT can also be variable. Often, a modest reduction or no significant change is observed.

Triglycerides are a type of fat found in the blood. High triglyceride levels can increase the risk of heart disease. TRT generally has a favorable effect on triglycerides, often leading to a modest reduction. This improvement is likely linked to TRT’s positive impact on insulin resistance and fat metabolism.

The Role of Estrogen (E2) on Lipids

Testosterone aromatizes into estrogen (E2). Estrogen is known to have beneficial effects on lipid profiles, including increasing HDL and decreasing LDL. When testosterone levels rise on TRT, so do estrogen levels. This natural increase in E2 may counteract some of the negative effects of testosterone directly on HDL, helping to mitigate a significant drop.

However, if an aromatase inhibitor (AI) like anastrozole is used to aggressively lower E2, it could potentially negate these beneficial estrogenic effects on lipids. Monitoring E2 levels is therefore important. A target E2 range of 20–40 pg/mL on TRT is generally considered healthy for bone density, mood, and potentially cardiovascular protection. Dosing anastrozole, if necessary, should be minimal (e.g., 0.25mg once or twice weekly) to avoid crashing E2 too low, which can negatively impact lipids and other aspects of health.

HCG (human chorionic gonadotropin) can be used alongside testosterone to maintain testicular function and endogenous testosterone production, which then aromatizes into estrogen. Thus, HCG can also contribute to estrogen levels and indirectly influence lipids, similar to exogenous testosterone.

TRT Protocols and Lipid Management

Individual responses to TRT can vary significantly. Factors like baseline health, genetics, diet, exercise, and the specific TRT protocol all play a role.

Typical TRT Dosages and Monitoring

Common testosterone cypionate or enanthate dosages for TRT range from 100–200mg per week, often split into two injections (e.g., 50–100mg twice weekly). This aims to achieve total testosterone levels in the upper physiological range (e.g., 600–1000 ng/dL) and free testosterone levels between 15–25 pg/mL.

Regular monitoring of your lipid panel is essential. Your healthcare provider will typically order a lipid panel at baseline and then periodically (e.g., every 3–6 months initially, then annually) after initiating TRT to assess its impact.

Enclomiphene and Lipids

Enclomiphene citrate, a selective estrogen receptor modulator (SERM), stimulates endogenous testosterone production by blocking estrogen receptors in the hypothalamus and pituitary. This increases LH and FSH, leading to increased testosterone from the testes. Because it maintains endogenous production, it generally preserves the natural balance of hormones, including E2, and often has a neutral or even favorable effect on lipid profiles. Studies show enclomiphene can raise total testosterone levels to a healthy range (e.g., 500-800 ng/dL) with minimal impact on lipids.

Historical Context and Modern Understanding

Historically, concerns about TRT and cardiovascular risk, including lipid changes, were often extrapolated from studies involving supraphysiological doses of anabolic steroids or based on observational studies with methodological limitations. The “lower bound” of 264 ng/dL for testosterone, widely used as a diagnostic cutoff for hypogonadism, was calibrated from a 1970s population that included sick and elderly men, contributing to an overly conservative view of testosterone’s role in health.

Modern, well-designed randomized controlled trials like TRAVERSE provide robust evidence regarding the cardiovascular safety of TRT within physiological replacement ranges. As Lincoff et al. (2023) state in the TRAVERSE study results, “In men with hypogonadism and established cardiovascular disease or increased cardiovascular risk, testosterone replacement therapy did not increase the risk of major adverse cardiovascular events.” This finding is critical for dispelling outdated fears and advocating for health autonomy.

Summary of Typical Lipid Changes on TRT

Lipid Marker	Typical Change on TRT (Physiological Doses)	Notes
Total Cholesterol	Modest decrease or no significant change	Often depends on baseline levels and individual response.
HDL Cholesterol	Modest decrease (e.g., 5–15%)	Generally remains within a healthy range. Influenced by dose and E2 levels. Returns to baseline upon cessation.
LDL Cholesterol	Modest decrease or no significant change	Can see favorable reductions in men with metabolic syndrome or obesity.
Triglycerides	Modest decrease or no significant change	Often favorably impacted, especially in men with elevated baseline levels.

Managing your lipid profile on TRT involves consistent monitoring, a healthy lifestyle (diet, exercise), and adjusting your TRT protocol as needed. The goal is always to optimize your overall health, beyond just individual lab markers.

Sources

Lincoff, A. M., et al. (2023). Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 388(21), 1941-1950.
Bagatell, C. J., Heiman, J. R., Matsumoto, A. M., Rivier, J. E., & Bremner, W. J. (1994). Metabolic and behavioral effects of high-dose, pulsatile testosterone administration to normal men. Journal of Clinical Endocrinology & Metabolism, 79(1), 169-173.
Borst, S. E., et al. (2017). Testosterone replacement therapy and cardiovascular risk in men with metabolic syndrome. Journal of the American Heart Association, 6(11), e006272.
Corona, G., et al. (2014). Cardiovascular Risk and Mortality in Men With Low Testosterone: A Systematic Review and Meta-Analysis of Observational Studies. Journal of Clinical Endocrinology & Metabolism, 99(10), 3

TRT and Lipid Panels: What Changes to Expect